Cintex Services, LLC and Senores Pharmaceuticals, Inc. Introduce Chlorzoxazone USP, 250 mg Tablets in US Market
ATLANTA, Oct. 5, 2021 / PRNewswire / – Cintex Services, LLC and Senores Pharmaceuticals, Inc. announce the launch of Chlorzoxazone Tablets USP, 250 mg, a therapeutic equivalent version of Paraflex (Chlorzoxazone) 250 mg in the U.S. market. The product will be distributed by Cintex Services, LLC.
Chlorzoxazone is indicated as an adjunct to rest, physiotherapy and other measures for the relief of discomfort associated with acute and painful musculoskeletal conditions. Senores Pharmaceuticals, Inc. has obtained a Competitive Generic Therapy (CGT) designation for Chlorzoxazone Tablets USP, 250 mg, therefore, with this approval, Senores is the first approved applicant for such competitive generic therapy and is eligible for 180 CGT exclusivity days during commercial marketing. “We are pleased to announce the commercial launch of Chlorzoxazone Tablets USP, 250 mg in the United States through our marketing partner,” said Dhananjay Barot, Director, Senores Pharmaceuticals, Inc. “We will continue our efforts to to be a and reliable supplier of this product, ” said Swapnil Shah, Managing Director, Senores Group.
“We are thrilled with this launch,” said Suzanne Miller, Managing Director of Cintex Services, LLC. “We are delighted to partner with Senores to create access to this product and expand our basket of offerings in the US market. The annual US market size for Chlorzoxazon Tablets USP, 250 mg, was approximately US $ 83 million.
About Senores Pharmaceuticals, Inc. Senores Pharmaceuticals, Inc., based in Georgia, USA, is one of the fastest growing pharmaceutical companies in the US market. Currently, the company has more than 15 products launched commercially or registered with the USFDA.
For more information about Senores Pharmaceuticals, Inc., please visit www.senorespharma.com About Cintex Services, LLC’s products. With more than 10 products currently on the market, Cintex continues to grow and provide low cost alternatives to consumers.
Photo: https://mma.prnewswire.com/media/1652902/Cintex_Senores_Pharma.jpg PWR PWR
(This story was not edited by Devdiscourse staff and is auto-generated from a syndicated feed.)